Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
Year: 2023
Type: letter
Abstract: We read with interest the article entitled, ‘H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma’ (DMG).[1][1] In this report, the investigators isolated an H3.3K27M-specific T cell receptor (TCR) from transgenic mice expressing a diverse
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W4353018844